Company: CPMV
Filing Date: 2025-04-15
Form Type: 10-K
Source: 0001683168-25-002584
Chunk: 36

Company: Mosaic ImmunoEngineering Inc.
Filing Date: 2025-04-15
Form: 10-K
Item: Item 1
Chunk 36
---
 new product candidates and license those
rights, then we expect to expand our research and development function, as well as our corporate operations, and as a result, we may encounter
difficulties in managing our growth, which could disrupt our operations. 

If we are able to raise sufficient capital and potentially
license or acquire new technologies, we would expect to experience significant growth in the number of our employees and the scope of
our operations, particularly in the areas of product manufacturing, preclinical research, clinical development, and regulatory affairs,
as capital resources become available. To manage our anticipated future growth, we must also implement and improve our managerial, operational
and financial systems, identify new facilities and continue to recruit and train additional qualified personnel. Due to our limited financial
resources, we may not be able to effectively manage the expansion of our operations or recruit and train additional qualified personnel.
The expansion of our operations may lead to significant costs and may divert our management and business development resources. Any inability
to manage growth could delay the execution of our business plans or disrupt our operations.

We may face risks related to securities litigation
that could result in significant legal expenses and settlement or damage awards.

We may in the future become subject to claims and
litigation alleging violations of the securities laws or other related claims, which could harm our business and require us to incur significant
costs. We are generally obliged, to the extent permitted by law, to indemnify our current and former directors and officers who are named
as defendants in these types of lawsuits. Regardless of the outcome, litigation may require significant attention from management and
could result in significant legal expenses, settlement costs or damage awards that could have a material impact on our financial position,
results of operations and cash flows.

 21 

Risks Related
to Our Common Stock 

There is a substantial lack of liquidity of our
common stock and volatility risks, and because there is no active public trading market for our common stock, you may not be able to resell
your common stock.

Our common stock is not listed on any securities exchange
and is quoted on the OTC Pink Open Market (“OTC Pink”) under the symbol “CPMV.” The trading volume of our common
stock historically has been limited and sporadic, and the stock prices have been volatile. There can be no assurance that there will be
an active market for our shares of common stock either now or in the future or that stockholders will be able to liquidate their investment
or liquidate it at